Viatris emerged from Pfizer’s merger with Mylan and Upjohn, trading since 2020, with a market cap of $11 billion. See why I rate VTRS stock a buy.
Viatris: A Unique S&P 500 ‘Fallen Angel’ With Intriguing Potential
view original post
Viatris emerged from Pfizer’s merger with Mylan and Upjohn, trading since 2020, with a market cap of $11 billion. See why I rate VTRS stock a buy.